Unibest

Pharmaceutical intermediates

Ensifentrine Intermediates

6 pharmaceutical intermediates for Ensifentrine. Indication: Chronic Obstructive Pulmonary Disease.

提交项目All intermediates

About Ensifentrine

Originator
Vernalis Plc
Indication
Chronic Obstructive Pulmonary Disease
Approved Date
06/26/2024
NCE Patent
06/26/2029
DS/DP
08/21/2031

Available intermediates

6 intermediates currently listed for Ensifentrine. Request specifications, documentation or a quotation for any item below.

Ensifentrine intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3,4-Dimethoxyphenethylamine120-20-7 //
2-Chloro-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-one75535-96-5//
N-(2-Bromoethyl)phthalimide574-98-1//
2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(3,4-dimethoxyphenyl)-298680-49-6//
2,4,6-Trimethylaniline88-05-1//
9,10-dimethoxy-2-(2,4,6-trimethylanilino)-6,7-dihydro-4H- pyrimido(6,1-a)isoquinolin-4-one76536-66-8//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Ensifentrine?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →